Innovating Works

UDSL

Desconocido
PHARMA-COG: Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the earl... Universit Lille 2 Droit et Sant participó en un FP6 PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies...
2010-01-01 - 2015-12-31 | Financiado
IMPROVINGADHERENCE: Improving medical treatment adherence taking into account patients perception of uncertainty in t... Universit Lille 2 Droit et Sant tramitó un FP7 Non-adherence, defined as the discrepancy between patients' behaviour and medical prescriptions, is a massive public health issue, the conse...
Financiado
MEMOSAD: Memory loss in Alzheimer disease underlying mechanisms and therapeutic targets Universit Lille 2 Droit et Sant participó en un FP7 MEMOSAD aims at defining the molecular mechanisms of Abeta- and Tau-induced synaptotoxicity and at developing disease-modifying therapeutics...
Financiado
Commodity12: COntinuous Multi parametric and Multi layered analysis Of DIabetes TYpe 1 2 Universit Lille 2 Droit et Sant participó en un FP7 In COMMODITY12 we will build a multi-layered multi-parametric infrastructure for continuous monitoring of diabetes type 1 and 2. The COMMOD...
Financiado
PHARMA-COG: Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the earl... Universit Lille 2 Droit et Sant participó en un FP7 PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies...
Financiado
ALLFUN: Fungi in the setting of inflammation allergy and autoimmune diseases Translating basic science into... Universit Lille 2 Droit et Sant participó en un FP7 The ALLFUN proposal aims at defining the cellular and molecular mechanisms by which ubiquitous airborne or commensal fungi contribute to im...
Financiado
GEPIDIAB: Genetics and epigenetics of Type 2 Diabetes physiology Universit Lille 2 Droit et Sant participó en un FP7 Failure to elucidate Type 2 Diabetes (T2D) physiology frustrates efforts to improve therapeutics. Although GWAS has identified 40 T2D genes,...
Financiado
PSIP: PATIENT SAFETY THROUGH INTELLIGENT PROCEDURES IN MEDICATION Universit Lille 2 Droit et Sant participó en un FP7 Adverse Drug Events (ADE) due to product safety problems, and medication errors due to human factors (HF) are a major Public Health issue. T...
Financiado
UNIVACFLU: Universal Flu Vaccine Universit Lille 2 Droit et Sant participó en un FP7 Currently licensed influenza vaccines promote an effective antibody response, but only against influenza virus strains that antigenically ma...
Financiado
CONSIDER: CIVIL SOCIETY ORGANISATIONS IN DESIGNING RESEARCH GOVERNANCE Universit Lille 2 Droit et Sant participó en un FP7 Broader stakeholder engagement in technical and scientific research is desirable for a variety of reasons. Civil Society Organisations (CSOs...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.